This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Pindolol

Read time: 1 mins
Marketing start date: 18 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

4

Spl Product Data Elements

Pindolol Pindolol PINDOLOL PINDOLOL SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM LAURYL SULFATE OFF-WHITE ROUND 10;63 Pindolol Pindolol PINDOLOL PINDOLOL SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM LAURYL SULFATE OFF-WHITE ROUND 10;64

Application Number

ANDA209866

Brand Name

Pindolol

Generic Name

Pindolol

Product Ndc

70771-1134

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1134-1 in bottle of 100 Tablets Pindolol Tablets USP, 5 mg Rx only 100 Tablets NDC 70771-1135-1 in bottle of 100 Tablets Pindolol Tablets USP, 10 mg Rx only 100 Tablets container label of 100 tablets - 5 mg container label of 100 tablets - 10 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.